1Harper KD, Weber TJ. Secondary osteoporosis. Diagnostic considerations [ J ]. Endocrino Metah Clio North Am, 1998,27 (2) :325-348.
2Nih Consensus Development Panel on Osteoporosis Prevention D Therapy. Osteoporosis prevention, diagnosis, and therapy [ J ]. JAMA, 2001,285 (6) :785-795.
3Giusti A, Barone A, Pioli G, et al. Alendronate and indapamide alone or in combination in the nmnagement of hyperealciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments [ J 1- Nephrol Dial Transplant, 2009,24 ( 5 ) : 1472 -1477.
4Kanis JA, Johansson H, Oden A, et al. Guidance tbr theadjustmcnt of FRAX according to the dose of glucocorticoids [ J ]. Osteoporos Int, 2011,22(3) :809-816.
5Hofl~auer LC ,Coil F, Riggs BL, et al. Stimulation of osteoprolegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells :potential paracrinemechanisms of glucocorticoid- induced osteoporosis [ J ]. Endocrinology, 1999,140 (10) :43824389.
6Canalis E. Wnt signalling in ostcoporosis: mechanisms and novel therapeutic approaches[ J]. Nat Rev Endocfinol,2013,9(10) :575-583.
7Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell.., and more[ J]. Endocr Rev ,2013,34(5 ) :658-690.
8Lekamwasam S, Adachi JD, Agnusdei D, et al. Joint IOFEGIOGWG. A framework lbr the development of guidelines for the management of glococorticnid-ioduced osteoporosis [ J ]. Osteoporos Int, 2012,23 ( 9 ) : 2257 -2276..
